The survival rate of NSCLC patients with serum miR-183 expression level < 1.77 after EGFR-TKI treatment was higher than those with serum miR-183 expression level ≥ 1.77 before treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.